CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

COVID-19 test, polymerase chain reaction for SARS-CoV-2Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug845 Thrombin Generation Assay (TGA) Wiki 1.00
drug847 Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki 1.00

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D004211 Disseminated Intravascular Coagulation NIH 0.58
D020141 Hemostatic Disorders NIH 0.50
D001778 Blood Coagulation Disorders NIH 0.50
D016638 Critical Illness NIH 0.26
D014777 Virus Diseases NIH 0.11
D007239 Infection NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 SARS-CoV-2 Surveillance of Patients and Healthcare Workers at the Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark

Doctors, nurses and staff members of ear-nose and throat (ENT) departments are at high risk due to aerosol-inducing diagnostic procedures and surgery during the COVID-19 epidemic. Reports from China, Spain, Italy and England report of fatal cases among ENT specialists. With a concurrent lack of personal protection, it is of paramount importance to identify patients and healthcare workers at an early stage to prevent a COVID-19 outbreak in the department. A baseline study of all healthcare workers has been performed. Follow-up will be accomplished by interval testing, antibody measurements and REDcap Covid-19 questionnaires. All patients at risk of carrying SARS-CoV-2, or who are candidates for high-risk airway surgery will be tested. Infection control measures at the department will be implemented progressively according to the real-time surveillance results from both patients and healthcare workers.

NCT04356560 COVID-19 Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2

Primary Outcomes

Description: Change from baseline in number of healthcare workers positive for SARS-CoV-2. Measured by repetitive naso/oropharyngeal swab tests of all active healthcare workers at the department.

Measure: Incidence of healthcare workers with SARS-CoV-2

Time: 6 months

Description: Change from baseline in number of patients positive for SARS-CoV-2. Measured by naso/oropharyngeal swab tests

Measure: Incidence of ENT patients with SARS-CoV-2

Time: 6 months

Description: Incidence and prevalence of SARS-CoV-2 antibodies by repetitive blood samples testing SARS-CoV-2 antibody levels of immunoglobulin G and immunoglobulin M

Measure: Development of SARS-CoV-2 antibodies among healthcare workers

Time: 6 months

Secondary Outcomes

Description: Compare number of positive questionnaires with number of positive oro/nasopharyngeal swab test and antibody tests

Measure: Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers

Time: 6 months

Description: Change from baseline in total number of complications to upper respiratory tract infections (URTI). Proportion of SARS CoV-2 positives among patients with URTI compared to proportion of SARS CoV-2 positive among ENT patients with non-infectious disease (eg cancer)

Measure: SARS CoV-2 and bacterial super infections in upper respiratory airways

Time: 6 months

No related HPO nodes (Using clinical trials)